|

JNJ-78278343 Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: KLK2-CD3, Pasritamig

Pipeline

Phase 1: 3

Top Sponsors

  • Janssen Research & Development, LLC3

Indications

  • Cancer3
  • Metastatic Hormone-sensitive Prostate Cancer1
  • Metastatic Castration-resistant Prostate Neoplasms1
  • Advanced Prostate Cancer1
  • Prostatic Neoplasms1

Sarasota, Florida2 trials

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Florida Cancer Specialists

Phase 1
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Florida Cancer Specialists

Phase 1

Aurora, Colorado1 trial

A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer

University of Colorado Anschutz Medical Campus

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.